Alvotech Willing And Able To Go Stride For Stride On Pembrolizumab Manufacturing
Potential Regulatory Hurdle Not Concern For Now For Icelandic Firm
Alvotech stepped into its 2023 annual financing results call bursting with positive news and momentum, on the back of obtaining USFDA approval for its biosimilar Humira product and a bullish outlook for its strong pipeline of biosimilar candidates.
